Adial Pharmaceuticals IncNASDAQ:ADIL
- LAST PRICE2.6600
- TODAY'S CHANGE (%)-0.1199 (-4.3131%)
- Bid / Lots2.5000/ 20
- Ask / Lots2.7800/ 3
- Open / Previous Close2.8750 / 2.7799
- Day Range
- 52 Week Range
- Volume12,263
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | ADIL |
|---|---|---|
| 09:38 ET | 2789 | 2.9511 |
| 09:41 ET | 624 | 2.88 |
| 09:57 ET | 100 | 2.88 |
| 12:52 ET | 100 | 2.8541 |
| 01:01 ET | 221 | 2.79 |
| 01:10 ET | 1572 | 2.72 |
| 01:30 ET | 900 | 2.77 |
| 02:13 ET | 225 | 2.73 |
| 02:27 ET | 514 | 2.71 |
| 02:38 ET | 1688 | 2.713 |
| 03:03 ET | 100 | 2.7 |
| 03:59 ET | 100 | 2.66 |
Sep 28, 2023
Adial Pharmaceuticals to Host a Virtual Key Opinion Leader Webinar to Discuss the Unmet Need in Alcohol Use Disorder, from 7:00AM ET on Thursday Sep 28, 2023 by Dow Jones
7:00AM ET on Thursday Sep 28, 2023 by Dow Jones
Sep 5, 2023
Adial Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference, from 8:30AM ET on Tuesday Sep 05, 2023 by Dow Jones
8:30AM ET on Tuesday Sep 05, 2023 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Adial Pharmaceuticals Inc | 3.1M | -0.3x | --- |
Cell MedX Corp | 3.1M | -3.9x | --- |
ContraFect Corp | 3.0M | 0.0x | --- |
Phio Pharmaceuticals Corp | 3.3M | -0.1x | --- |
Evolutionary Genomics Inc | 3.0M | -1.3x | --- |
Proteo Inc | 3.0M | 0.0x | --- |
Company Information
Adial Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of therapeutics for the treatment or prevention of addiction and related disorders. The Company’s drug candidate, AD04, is being developed as a therapeutic agent for the treatment of alcohol use disorder (AUD). AD04 is used for the treatment of AUD in subjects with certain target genotypes, which were identified using its companion diagnostic genetic test. AD04 is a genetically targeted, serotonin-3 receptor antagonist, a therapeutic agent for the treatment of AUD. The Company’s AD04 also has the potential to treat other addictive disorders such as opioid use disorder, gambling, and obesity. The Company is also developing adenosine analogs for the treatment of pain and other disorders.
Contact Information
- Headquarters
- 1180 SEMINOLE TRAIL, SUITE 495CHARLOTTESVILLE, VA, United States 22901
- Phone
- 434-422-9800
- Fax
- 302-655-5049
Executives
- Independent Chairman of the Board
- Kevin Schuyler
- President, Chief Executive Officer, Director
- Cary Claiborne
- Chief Financial Officer, Chief Operating Officer
- Joseph Truluck
- Chief Financial Officer, Treasurer, Company Secretary
- Joseph Truluck
- Chief Medical Officer
- Bankole Johnson
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $3.1M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 1.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.14 |
EPS | $-9.15 |
Book Value | $3.07 |
P/E Ratio | -0.3x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
